UNSPSC 51263154: Bucindolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C22H25N3O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SH683G4QII, chemically known as 2-(2-hydroxy-3-((2-(3-indolyl)-1,1-dimethylethyl)amino)propoxy)benzonitrile hydrochloride but more generally known as bucindolol hydrochloride, which bears US NIH Compound Identifier 51044. European Medicines Agency schedules Bucindolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00886MIG.

Most nations, for tariff and trade purposes, schedule bucindolol hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, BUCINDOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)(CC1C[NH]C2C1CCCC2)NCC(COC3CCCCC3C#N)O.CL.

UNSPSC 51263154 Bucindolol hydrochloride is a Commodity code that sits at the lowest tier of the taxonomy, yet the recent state and local contract opportunities posted under it show no alignment with its pharmaceutical scope. The two opportunities on record — one from Seminole County, Florida seeking naloxone and drug deactivation systems, and one from the Texas Health and Human Services Commission requesting information on direct-to-manufacturer prescription programs — represent public health and pharmacy benefit procurement activity that does not match the code's nominal designation of a specific beta-blocker medication. State and local governments do not appear to be soliciting bucindolol hydrochloride itself under this code; the recent postings suggest either a data-entry error in UNSPSC classification or that this code carries little to no current purchasing activity aligned with its intended commodity.

The geographic activity appears limited to Texas and Florida based on the two posted opportunities, with no pattern of repeat buyers or broad multi-jurisdiction procurement evident. The Seminole County IFB (IFB60459723LAS) closed on July 26, 2023, and the Texas HHS RFI (HHS0017013) was an information-gathering mechanism posted in early April 2026 with no formal response deadline structure. Neither opportunity represents active buying of the pharmaceutical specified in the code name, and no other recent state or local solicitations under this code are documented in the source material. Firms evaluating this code should verify its actual use in current procurement systems; the code appears misapplied in available records and does not reflect genuine market demand for bucindolol hydrochloride at the state and local level.